TKTeruo Kawada

Teruo Kawada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Teruo Kawada has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Nobuyuki Takahashi

    Department of Nutritional Science and Food Safety, Faculty of Applied Bioscience, Tokyo University of Agriculture, 1-1-1 Sakuragaoka, Setagaya-ku, Tokyo 156-8502, Japan

    7 shared publications
  • Shizuka Hirai

    Laboratory of Molecular Function of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, Kyoto, Japan

    6 shared publications
  • Tsuyoshi Goto

    Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, Kyoto 611-0011, Japan

    6 shared publications
  • Joo‐Young Lee

    Laboratory of Molecular Function of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, Kyoto, Japan

    3 shared publications
  • Min‐Sook Kang

    Laboratory of Molecular Function of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, Kyoto, Japan

    3 shared publications
  • Taku Uemura

    Laboratory of Molecular Function of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, Kyoto, Japan

    3 shared publications

Latest Publications

  • Auraptene regulates gene expression involved in lipid metabolism through PPARα activation in diabetic obese mice

    by Nobuyuki Takahashi, Mari Senda, Shan Lin, Tsuyoshi Goto, Masamichi Yano, Takao Sasaki, Shigeru Murakami, Teruo Kawada

    Scope: Peroxisome proliferator‐activated receptor‐α (PPARα) is a key regulator of circulating lipid level. Thus, various food‐derived compounds that activate PPARα as agonists have been screened and characterized.Methods and results: We investigated the effects of auraptene, a citrus‐derived compound serving as a PPARα agonist in vitro, on abnormalities in lipid and glucose metabolisms. In high‐fat‐diet (HFD)‐fed KK‐Ay diabetic obese mice, auraptene treatment suppressed hyperlipidemia and triglyceride accumulation in the liver and skeletal muscle, and increased the mRNA expression levels of the PPARα target genes involved in fatty acid oxidation in the liver and skeletal muscle. Moreover, the adipocyte size in the auraptene‐treated mice was significantly smaller than that in the control HFD‐fed mice resulting in the improvement of HFD‐induced hyperglycemia and abnormalities in glucose tolerance.Conclusions: These findings indicate that auraptene activates PPARα also in vivo and its treatment may improve abnormalities in lipid and glucose metabolisms, suggesting that auraptene is a valuable food‐derived compound for managing metabolic disorders.


  • Dehydroabietic acid activates peroxisome proliferator‐activated receptor‐γ and stimulates insulin‐dependent glucose uptake into 3T3‐L1 adipocytes

    by Nobuyuki Takahashi, Ran Yao, Min‐Sook Kang, Mari Senda, Chieko Ando, Kanako Nishimura, Tsuyoshi Goto, Shizuka Hirai, Yoichiro Ezaki, Teruo Kawada

    Dehydroabietic acid (DAA) is a food‐derived terpenoid with various bioactivities. Our previous study has revealed that DAA activates peroxisome proliferator‐activated receptor‐γ (PPARγ) in luciferase assay and suppresses chronic inflammation in obese adipose tissues. In this study, we examined the effects of DAA on adipocyte differentiation. DAA treatment stimulated the adipocyte differentiation of 3T3‐L1 preadipocytes. The DAA treatment increased the mRNA expression levels of adipocyte differentiation marker genes such as aP2, lipoprotein lipase (LPL), and PPARγ. In particular, the expression level of adiponectin, which is an adipocytokine with stimulatory effects on insulin sensitivity, was increased at both the mRNA and protein levels by the DAA treatment. Moreover, the DAA treatment stimulated insulin‐dependent glucose uptake into differentiated 3T3‐L1 adipocytes. These findings indicate that DAA stimulates adipocyte differentiation and insulin sensitivity in 3T3‐L1 cells, suggesting that DAA is a valuable food‐derived compound for the management of metabolic syndrome.


  • 9‐oxo‐10(E),12(E)‐octadecadienoic acid derived from tomato is a potent PPAR α agonist to decrease triglyceride accumulation in mouse primary hepatocytes

    by Young‐Il Kim, Shizuka Hirai, Haruya Takahashi, Tsuyoshi Goto, Chie Ohyane, Taneaki Tsugane, Chiaki Konishi, Takashi Fujii, Shuji Inai, Yoko Iijima, et al.

    Scope: Tomato is one of the most common crops worldwide and contains many beneficial compounds that improve abnormalities of lipid metabolism. However, the molecular mechanism underlying the effect of tomato on lipid metabolism is unclear. It has been commonly accepted that peroxisome proliferator‐activated receptor α (PPARα) is one of the most important targets for ameliorating abnormalities of lipid metabolism. Therefore, we focused on the activation of PPARα and attempted to detect active compounds activating PPARα in tomato.Methods and results: To identify such active compounds, we screened fractions of tomato extracts using PPARα luciferase reporter assay. One fraction, rechromatographed‐fraction eluted in 57 min (RF57), significantly increased PPARα reporter activity, in which a single compound is detected by LC/MS analysis. On the basis of LC/MS and NMR analyses, we determined the chemical structure of the active compound in RF57 as 9‐oxo‐10(E),12(E)‐octadecadienoic acid (9‐oxo‐ODA). The RF57 fraction significantly increased the mRNA expression levels of PPARα target genes involved in fatty acid oxidation and O2 consumption in mouse primary hepatocytes. Furthermore, RF57 inhibited cellular triglyceride accumulation in the hepatocytes.Conclusion: These findings suggest that tomatoes containing 9‐oxo‐ODA that acts on PPARα are valuable for ameliorating abnormalities of lipid metabolism.


  • Diosgenin present in fenugreek improves glucose metabolism by promoting adipocyte differentiation and inhibiting inflammation in adipose tissues

    by Taku Uemura, Shizuka Hirai, Noriko Mizoguchi, Tsuyoshi Goto, Joo‐Yong Lee, Keiko Taketani, Yuki Nakano, Jinji Shono, Shohei Hoshino, Nobuaki Tsuge, et al.

    In obesity, adipocyte hypertrophy and chronic inflammation in adipose tissues cause insulin resistance and type‐2 diabetes. Trigonella foenum‐graecum (fenugreek) can ameliorate hyperglycemia and diabetes. However, the effects of fenugreek on adipocyte size and inflammation in adipose tissues have not been demonstrated. In this study, we determined the effects of fenugreek on adipocyte size and inflammation in adipose tissues in diabetic obese KK‐Ay mice, and identified the active substance in fenugreek. Treatment of KK‐Ay mice with a high fat diet supplemented with 2% fenugreek ameliorated diabetes. Moreover, fenugreek miniaturized the adipocytes and increased the mRNA expression levels of differentiation‐related genes in adipose tissues. Fenugreek also inhibited macrophage infiltration into adipose tissues and decreased the mRNA expression levels of inflammatory genes. In addition, we identified diosgenin, a major aglycone of saponins in fenugreek to promote adipocyte differentiation and to inhibit expressions of several molecular candidates associated with inflammation in 3T3‐L1 cells. These results suggest that fenugreek ameliorated diabetes by promoting adipocyte differentiation and inhibiting inflammation in adipose tissues, and its effects are mediated by diosgenin. Fenugreek containing diosgenin may be useful for ameliorating the glucose metabolic disorder associated with obesity.


  • Diosgenin attenuates inflammatory changes in the interaction between adipocytes and macrophages

    by Shizuka Hirai, Taku Uemura, Noriko Mizoguchi, Joo‐Young Lee, Keiko Taketani, Yuki Nakano, Shohei Hoshino, Nobuaki Tsuge, Toshihiko Narukami, Rina Yu, et al.

    Obese adipose tissues are characterized by the enhanced infiltration of macrophages. It is considered that the paracrine loop involving monocyte chemoattractant protein‐1, tumor necrosis factor‐α, and the free fatty acid between adipocytes and macrophages establishes a vicious cycle that aggravates inflammatory changes and insulin resistance in obese adipose tissues. Diosgenin, a saponin aglycon found in a variety of plants, has anti‐inflammatory properties. In the present study, we examined the effect of diosgenin on the inflammatory changes in the interaction between adipocytes and macrophages. A coculture of 3T3‐L1 adipocytes and RAW 264 macrophages markedly enhanced the production of tumor necrosis factor‐α, monocyte chemoattractant protein‐1, and nitric oxide compared with the sum of their single cultures; however, treatment with diosgenin inhibited the production of these proinflammatory mediators. Diosgenin also suppressed the inflammation in RAW 264 macrophages that was induced by the conditioned medium derived from 3T3‐L1 adipocytes. Furthermore, diosgenin inhibited the conditioned medium‐induced degradation of inhibitor κB and the phosphorylation of c‐jun N‐terminal kinase in macrophages. These results indicate that diosgenin exhibits anti‐inflammatory properties in the interaction of adipocytes and macrophages by inhibiting the inflammatory signals in macrophages. Diosgenin may be useful for ameliorating the inflammatory changes in obese adipose tissues.


  • Dehydroabietic acid, a diterpene, improves diabetes and hyperlipidemia in obese diabetic KK‐Ay mice

    by Min‐Sook Kang, Shizuka Hirai, Tsuyoshi Goto, Kayo Kuroyanagi, Young‐Ii Kim, Kana Ohyama, Taku Uemura, Joo‐Young Lee, Tomoya Sakamoto, Yoichiro Ezaki, et al.

    Terpenoids, which are contained in a large number of dietary and herbal plants, have many biological effects. In this study, the effects of dehydroabietic acid (DAA), a diterpene, on glucose and lipid metabolism were examined using obese diabetic KK‐Ay mice. We showed here that DAA treatment decreased not only plasma glucose and insulin levels but also plasma triglyceride (TG) and hepatic TG levels. To examine the mechanism underlying the effects of DAA, the production of inflammatory cytokines was measured. It was shown that the DAA treatment suppressed the production of monocyte chemoattractant protein‐1 (MCP‐1) and tumor necrosis factor‐α (TNFα) (proinflammatory cytokines) and increased that of adiponectin (an anti‐inflammatory cytokine). As a result of the changes in the production of inflammatory cytokines caused by the DAA treatment, the accumulation of macrophages in adipose tissues was reduced. These results indicate that treatment with DAA improves the levels of plasma glucose, plasma insulin, plasma TG, and hepatic TG through the decrease in the macrophage infiltration into adipose tissues, suggesting that DAA is a useful food‐derived compound for treating obesity‐related diseases. © 2009 International Union of Biochemistry and Molecular Biology, Inc.


  • Auraptene, a citrus fruit compound, regulates gene expression as a PPARα agonist in HepG2 hepatocytes

    by Nobuyuki Takahashi, Min‐Sook Kang, Kayo Kuroyanagi, Tsuyoshi Goto, Shizuka Hirai, Kana Ohyama, Joo‐Young Lee, Teruo Kawada, Rina Yu, Masamichi Yano, et al.

    Citrus fruit compounds have various activities that improve pathological conditions in many tissues. In this study, we examined the effect of auraptene contained mainly in the peel of citrus on peroxisome proliferator‐activated receptor‐α (PPARα) activation. To examine effects of auraptene on the PPARα activation in hepatocytes, PPAR ligand assay system was developed using HepG2 hepatocytes, in which the endogenous PPARα expression level is very low. In the PPAR ligand assay, the addition of auraptene showed significant effects on the transactivation of GAL4/PPARα chimera proteins in a dose‐dependent manner. Actually, treatment with auraptene induced the up‐regulation of PPAR target genes, such as acyl‐CoA oxidase (ACO), carnitine‐palmitoyl transferase 1A (CPT1A) and acyl‐CoA synthetase (ACS), in PPARα‐expressing HepG2 hepatocytes. The regulation of gene expression was dependent on PPARα because mock‐transfected HepG2 hepatocytes showed no regulation. The up‐regulation of PPAR target gene expression by auraptene was sufficient to enhance oleic acid uptake into PPARα‐expressing HepG2 hepatocytes. These results indicate that auraptene acts as a PPARα agonist in hepatocytes and that auraptene may improve lipid abnormality through PPARα activation in the liver.